



ALL

IMAGES

VIDEOS

802,000 Results

Any time ▾

Osteoporosis in liver disease: pathogenesis and management

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892399>

Apr 06, 2016 · Treatment of viral liver disease associated osteoporosis appears to be a causal treatment geared to achieve **sustained suppression of hepatitis B virus replication or hepatitis C virus sustained viral response** [Arase et al. 2010]. It has been shown that the incidence of osteoporotic fractures in patients with hepatitis C is significantly reduced after successful ...

Cited by: 24

Author: Gabriela Handzlik-Orlik, Michał Holecki,...

Publish Year: 2016

Denosumab Prevents Osteoporosis in Autoimmune Liver ...

<https://www.empr.com/.../denosumab-prevents-osteoporosis-in-autoimmune-liver-diseases> ▾

Nov 11, 2016 · BOSTON, MA—Injections of **denosumab** every 6 months prevent **osteoporosis** in **patients** with primary biliary cholangitis and autoimmune hepatitis, with minimal adverse **effects**...

Author: Bryant Furlow

Effects of denosumab versus teriparatide in glucocorticoid ...

<https://www.sciencedirect.com/science/article/pii/S235218722030053X>

Our data suggest that teriparatide has better therapeutic **effects** than **denosumab** in GIO **patients** receiving bisphosphonates as pretreatment. Bone turnover markers have been used as a tool for monitoring **patients'** responses to **treatment** for **osteoporosis** (Eastell et al., 2018). Changes in bone turnover markers are associated with later changes in BMD.

Efficacy and Safety of 3-Year Denosumab Therapy for ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30904>

Aug 20, 2019 · **Osteoporosis** is a major complication in **patients** with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH). **Denosumab**, a fully human monoclonal antibody against the receptor activator of nuclear factor- κ B ligand (RANKL), increases bone mineral density (BMD) by inhibiting development and activity of osteoclasts and decreasing bone resorption.



ALL

IMAGES

VIDEOS

802,000 Results

Any time ▾

Osteoporosis in liver disease: pathogenesis and management

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892399>

Apr 06, 2016 · Treatment of viral liver disease associated osteoporosis appears to be a causal treatment geared to achieve **sustained suppression of hepatitis B virus replication or hepatitis C virus sustained viral response** [Arase et al. 2010]. It has been shown that the incidence of osteoporotic fractures in patients with hepatitis C is significantly reduced after successful ...

Cited by: 24

Author: Gabriela Handzlik-Orlik, Michał Holecki,...

Publish Year: 2016

Denosumab Prevents Osteoporosis in Autoimmune Liver ...

<https://www.empr.com/.../denosumab-prevents-osteoporosis-in-autoimmune-liver-diseases> ▾

Nov 11, 2016 · BOSTON, MA—Injections of **denosumab** every 6 months prevent **osteoporosis** in **patients** with primary biliary cholangitis and autoimmune hepatitis, with minimal adverse **effects**...

Author: Bryant Furlow

Effects of denosumab versus teriparatide in glucocorticoid ...

<https://www.sciencedirect.com/science/article/pii/S235218722030053X>

Our data suggest that teriparatide has better therapeutic **effects** than **denosumab** in GIO **patients** receiving bisphosphonates as pretreatment. Bone turnover markers have been used as a tool for monitoring **patients'** responses to **treatment** for **osteoporosis** (Eastell et al., 2018). Changes in bone turnover markers are associated with later changes in BMD.

Efficacy and Safety of 3-Year Denosumab Therapy for ...

<https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/hep.30904>

Aug 20, 2019 · **Osteoporosis** is a major complication in **patients** with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH). **Denosumab**, a fully human monoclonal antibody against the receptor activator of nuclear factor- κ B ligand (RANKL), increases bone mineral density (BMD) by inhibiting development and activity of osteoclasts and decreasing bone resorption.

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 56760

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Effects of denosumab treatment in chronic liver disease patients with osteoporosis

Chisato Saeki, Mitsuru Saito, Tsunekazu Oikawa, Masanori Nakano, Yuichi Torisu,
Masayuki Saruta, Akihito Tsubota

Abstract

BACKGROUND

Effective treatment of osteoporosis is essential for improving morbidity and health-related quality of life in chronic liver disease (CLD) patients. Denosumab has been shown to increase bone mineral density (BMD) and decrease the risk of osteoporotic fracture in the general population. However, there are few reports evaluating the efficacy of denosumab in CLD patients.

Match Overview

1	Internet 84 words crawled on 14-Jul-2020 link.springer.com	2%
2	Internet 73 words crawled on 31-Jul-2020 www.mdpi.com	2%
3	Internet 50 words crawled on 28-May-2020 bmcmusculoskeletdisord.biomedcentral.com	1%
4	Internet 29 words crawled on 31-Oct-2010 www.ncbi.nlm.nih.gov	1%
5	Internet 25 words crawled on 21-Jul-2017 ar.iiarjournals.org	1%
6	Internet 25 words crawled on 11-May-2015 toukastress.jp	1%
7	Crossref 20 words Sakae Tanaka. "Role of RANKL in physiological and patho... gical bone resorption and therapeutics targeting the RANKL	<1%
8	Internet 18 words crawled on 21-Mar-2019 www.science.gov	<1%



ALL

IMAGES

VIDEOS

802,000 Results

Any time ▾

Osteoporosis in liver disease: pathogenesis and management

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892399>

Apr 06, 2016 · Pathologic fracture in **osteoporosis** significantly affects quality of life and life expectancy. By some estimates, 40% of **patients with chronic liver disease** may experience osteoporotic fracture. In this study we review the pathogenesis, diagnosis and **treatment** of specific **liver disease** entities and their relation to **osteoporosis**.

Cited by: 25

Author: Gabriela Handzlik-Orlik, Michał Holecki, ...

Publish Year: 2016

Denosumab Prevents Osteoporosis in Autoimmune Liver ...

<https://www.empr.com/home/mpr-first-report/aasld...> ▾

Nov 11, 2016 · BOSTON, MA—Injections of **denosumab** every 6 months prevent **osteoporosis** in **patients** with primary biliary cholangitis and autoimmune hepatitis, with minimal adverse effects...

Author: Bryant Furlow

Denosumab - LiverTox - NCBI Bookshelf

<https://www.ncbi.nlm.nih.gov/books/NBK548424>

Side effects of denosumab are uncommon, but can include injection site reactions, back and joint pains, rash, diarrhea, nausea and vomiting and headache. Rare side effects include **severe infusion reactions**, **hypersensitivity reactions**, **anaphylaxis**, **hypocalcemia**, **osteonecrosis of the jaw** and **atypical femoral fractures**.

PEOPLE ALSO ASK

Can liver disease cause osteoporosis? ▾

How does osteoporosis affect the liver? ▾

Can denosumab be used for infection? ▾

Is denosumab metabolized by kidneys? ▾